U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07949474) titled 'Semaglutide in Alcohol Use Disorder' on Nov. 13.
Brief Summary: This is a 45-week, randomized, double-blind, placebo-controlled clinical trial designed to compare the effectiveness of semaglutide versus placebo on alcohol-related outcomes among 128 adults with alcohol use disorder (AUD) and obesity.
Study Start Date: May 01, 2027
Study Type: INTERVENTIONAL
Condition:
Alcohol Use Disorder (AUD)
Obesity
Intervention:
DRUG: Wegovy
Participants in this arm will receive 42 weeks of treatment with semaglutide
OTHER: Placebo
Participants in this arm will receive 42 weeks of placebo
Recruitment Status: NOT_YET_RECRUITING
Sponsor:...